Abbott Receives EU CE Mark for Automated Version of BG Medicine's Galectin-3 Test | GenomeWeb

Abbott this week received an EU CE mark for its automated version of BG Medicine's Galectin-3 protein biomarker assay.

The assay, which is intended as an aid in determining the prognosis of heart failure patients, will run on Abbott's ARCHITECT immunochemistry platform.

BG received a CE Mark and US Food & Drug Administration 510(k) approval for a manual version of the Galectin-3 test in 2010 and has since worked with Abbott, Alere, Siemens, and BioMérieux on automated versions of the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.